Cobra Bio-Manufacturing PLC
12 November 2003


For Immediate Release                                           12 November 2003


                           Cobra Biomanufacturing Plc


             COBRA GRANTED KEY EUROPEAN PATENT FOR DNA MANUFACTURE



Keele, UK: Cobra Biomanufacturing Plc (AIM:CBF), the international manufacturer
of biopharmaceuticals, announces today the grant of the European Patent 1159062.
from the European Patent Office.

This patent relates to the large-scale manufacture of plasmid DNA medicines and
vaccines and covers Cobra's unique device and methods for extraction and
purification.  DNA products are complex and extremely difficult to manufacture
at the high levels of scalability required for commercialisation and to the
rigorous quality standards required by the regulatory authorities.

The market for DNA medicines and vaccines is set to grow to in excess of  $4
billion by the end of the decade.

Cobra's leading position in plasmid DNA and the manufacture of other high value,
high potency biopharmaceutical products is maintained by continued innovation
and investment in novel manufacturing technologies.

David Thatcher, Chief Executive of Cobra, said:

"Cobra provides DNA manufacturing services which are second to none, our ability
to offer this service is dependent on our commitment to innovation and the
development of technology led manufacturing solutions.  The grant of this patent
in Europe is another important step forward in consolidating Cobra's position as
the leading manufacturer of plasmid DNA medicines and vaccines."


                                    - ENDS -


For further information please contact:


David Thatcher, CEO                         Cobra                               + 44 (0) 1782 714 181

Tim Anderson/Rebecca Dietrich               Buchanan Communications             + 44 (0) 207 466 5000



Notes to Editors

Cobra Biomanufacturing Plc is a leading international manufacturer of
biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides
innovative manufacturing solutions to the biopharmaceutical industry covering
DNA, virus, cellular therapeutics and recombinant protein products. Cobra  was
the first company to develop GMP (Good Manufacturing Practice) standard DNA
manufacture in Europe, with specific expertise in DNA medicines. A range of
unique, patented technologies, underpins this revenue generating business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange
in June 2002 raising #7 million and raised a further #5.25 million in May 2003
in order to further expand capacity in Oxford UK.

Statements contained within this press release may contain forward-looking
comments which involve risks and uncertainties that may cause actual results to
vary from those contained in the forward-looking statements.  In some cases, you
can identify such forward-looking statements by terminology such as 'may', '
will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', '
estimates', 'predicts', 'potential', or 'continue'.  Predictions and
forward-looking references in this press release are subject to the satisfactory
progress of research, which is, by nature, unpredictable. Forward projections
reflect management's best estimates based on information available at the time
of issue.

                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAKGMMMNMMGFZM